Aristides Capital LLC Makes New $217,000 Investment in Sutro Biopharma, Inc. (NASDAQ:STRO)

Aristides Capital LLC acquired a new stake in Sutro Biopharma, Inc. (NASDAQ:STROFree Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 50,476 shares of the company’s stock, valued at approximately $217,000.

Other large investors have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in Sutro Biopharma by 1,275.7% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,105,132 shares of the company’s stock worth $10,775,000 after buying an additional 2,879,412 shares during the last quarter. Kynam Capital Management LP lifted its stake in shares of Sutro Biopharma by 3.5% during the 3rd quarter. Kynam Capital Management LP now owns 1,552,675 shares of the company’s stock valued at $5,388,000 after buying an additional 52,675 shares in the last quarter. Acadian Asset Management LLC grew its stake in Sutro Biopharma by 18.2% in the 3rd quarter. Acadian Asset Management LLC now owns 773,867 shares of the company’s stock valued at $2,684,000 after buying an additional 119,399 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in Sutro Biopharma by 42.5% during the 4th quarter. Vontobel Holding Ltd. now owns 641,684 shares of the company’s stock valued at $2,753,000 after acquiring an additional 191,345 shares during the period. Finally, Panagora Asset Management Inc. lifted its position in shares of Sutro Biopharma by 22.4% during the fourth quarter. Panagora Asset Management Inc. now owns 451,692 shares of the company’s stock worth $1,938,000 after acquiring an additional 82,544 shares in the last quarter. 96.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on STRO. Bank of America assumed coverage on Sutro Biopharma in a report on Wednesday, May 8th. They set a “buy” rating and a $12.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price objective (down previously from $12.00) on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Oppenheimer reiterated an “outperform” rating and issued a $10.00 target price on shares of Sutro Biopharma in a research note on Wednesday, May 15th. Truist Financial decreased their price target on shares of Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, May 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.50.

View Our Latest Stock Analysis on STRO

Sutro Biopharma Stock Down 1.3 %

NASDAQ STRO opened at $3.71 on Friday. The stock’s 50 day moving average is $4.14 and its 200 day moving average is $4.12. The firm has a market capitalization of $303.44 million, a PE ratio of -1.97 and a beta of 1.24. Sutro Biopharma, Inc. has a twelve month low of $2.01 and a twelve month high of $6.13.

Sutro Biopharma (NASDAQ:STROGet Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.03). Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%. The firm had revenue of $13.01 million during the quarter, compared to analysts’ expectations of $11.57 million. On average, research analysts anticipate that Sutro Biopharma, Inc. will post -3.19 earnings per share for the current year.

Sutro Biopharma Company Profile

(Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Read More

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STROFree Report).

Institutional Ownership by Quarter for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.